McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

McKesson Corporation

McKesson Corporation (MCK) shares up 138.5% since Big Money bought big in May 2022.

See How McKesson Shares Rise with Money Flows

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why McKesson (MCK) is a Top Momentum Stock for the Long-Term

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock

McKesson Corporation (NYSE:MCK ) Analyst/Investor Day September 23, 2025 9:30 AM EDT Company Participants Brian Tyler - CEO & Director Britt Vitalone - Executive VP & CFO Kirk Kaminsky - President of The US Pharmaceutical & Specialty Solutions Business Joan Eliasek - President Jason Hammonds Kevin Kettler Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division George Hill - Deutsche Bank AG, Research Division Brian Tanquilut - Jefferies LLC, Research Division Charles Rhyee - TD Cowen, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Daniel Grosslight - Citigroup Inc., Research Division Erin Wilson Wright - Morgan Stanley, Research Division Eric Percher - Nephron Research LLC Steven Valiquette - Mizuho Securities USA LLC, Research Division Stephen Baxter - Wells Fargo Securities, LLC, Research Division Presentation Operator Today's presentation will include forward-looking statements. Please refer to the cautionary statements and to the risk factors of our most recent annual and periodic SEC filings for additional information concerning risk factors that could cause our actual results to differ materially from our forward-looking statements in today's presentation.

McKesson Corporation (MCK) Analyst/Investor Day Transcript

McKesson on Tuesday raised its profit forecast, as the U.S. drug distributor aims to focus on high-margin businesses such as cancer medicines to boost growth.

McKesson lifts annual profit forecast on plans to focus on high-margin businesses

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will host its 2025 Investor Day today, beginning at 9:30 AM ET. During the event, executive leadership will discuss the company's multi-year strategic priorities, growth strategies, and long-term business outlook. The Investor Day event will showcase how McKesson continues to accelerate long-term growth and deliver sustained value creation: Executing strategic priorities: Demonstrating significant progress, focusing on people and.

McKesson Corporation Highlights Strategic Growth Strategies and Unveils Updated Long-term Financial Targets at Investor Day

The latest trading day saw McKesson (MCK) settling at $698.31, representing a +1.19% change from its previous close.

McKesson (MCK) Rises Higher Than Market: Key Facts

McKesson said on Thursday it will restructure its operations into four main segments from the current quarter as the U.S. drug distributor aims to focus on high-margin businesses such as cancer medicines to boost growth.

Drug distributor McKesson to restructure segments to focus on high-margin businesses

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) today announced changes to its reportable segments and organizational structure, effective in the second quarter of fiscal year 2026. The new reporting structure enhances strategic alignment and transparency, supporting optimizing portfolio management to drive sustainable long-term value creation for shareholders. “McKesson has a long history of leadership in healthcare, continuously evolving to meet the needs of our customers, pr.

McKesson Announces New Organizational Structure

Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.

Is Trending Stock McKesson Corporation (MCK) a Buy Now?

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.

4 Dental Supplies Stocks Likely to Gain Amid Rising Tariff Risks

Here's Why McKesson (MCK) is a Strong Value Stock

Everybody loves dividends, as they provide a passive income stream, limit drawdowns in other positions, and provide more than one way to profit from an investment.

Dividend Watch: 3 Companies Boosting Payouts

McKesson beats on Q1 earnings and raises FY26 EPS view, but shares slip as gross margin narrows and spin-off plans weigh on investors' sentiment.

MCK Stock Down Despite Q1 Earnings Beat & Raised '26 EPS View

While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, McKesson (MCK) Q1 Earnings: A Look at Key Metrics

McKesson Corporation (NYSE:MCK ) Q1 2026 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Brian S. Tyler - CEO & Director Britt J.

McKesson Corporation (MCK) Q1 2026 Earnings Call Transcript

McKesson (MCK) came out with quarterly earnings of $8.26 per share, beating the Zacks Consensus Estimate of $8.23 per share. This compares to earnings of $7.88 per share a year ago.

McKesson (MCK) Surpasses Q1 Earnings and Revenue Estimates

U.S. drug distributor McKesson raised its annual profit forecast and beat Wall Street earnings estimates on Wednesday, banking on robust demand for specialty medicines.

Mckesson lifts annual profit forecast on robust demand for specialty drugs

Real-time stock quote and overview for MCK